Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06305247 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
A Phase 1 study of Colorectal Cancer and Melanoma, sponsored by Ipsen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 220
- Enrollment target
- 12
- Study locations
NCT06305247: Recruiting Phase 1 study of Colorectal Cancer and Melanoma, sponsored by Ipsen.
NCT06305247 is a Phase 1 study of Colorectal Cancer and Melanoma that is actively recruiting participants, run by Ipsen. The registered enrollment target is 220 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (86% lower). The trial reports 12 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06305247, a Phase 1 study of Colorectal Cancer and Melanoma, is actively recruiting participants, sponsored by Ipsen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 220 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places, including cancers in organs or tissues that have spread from their original site to nearby tissues or other parts of the body. In this study, all participants will receive the study drug, which will be taken by mouth (orally).
Conditions Studied
Interventions
- DRUG IPN01194
Study Locations (12)
Other
- Centre Léon Bérard - Lyon - Lyon
- Paris Saint-Louis - Paris
- Institut de Cancerologie de l'Ouest (St-Herblain) - Saint-Herblain
- IGR-Villejuif - Villejuif
- Barcelona - Val D'Hebron - Barcelona
- Fundacion Jimenez Diaz - Madrid - Madrid
- M.D. Anderson Cancer Center Madrid - Madrid
California
- The Angeles Clinic and Research Institute - California - Los Angeles
- UC San Diego Health System - La Jolla - San Diego
Connecticut
- Yale Cancer Center - New Heaven - New Haven
Tennessee
- Sarah Cannon Research Institute (SCRI) - Nashville - Nashville
Virginia
- Virginia Cancer Specialist - Fairfax
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2024-04-03 |
| Est. Completion | 2028-03-20 |
| Phase | Phase 1 |
What NCT06305247 shows while recruiting
NCT06305247 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (86% lower).
The record links to 5 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 1 intervention - of which IPN01194 is the first listed.
NCT06305247 lists 12 locations in 5 states (Other, California, Connecticut).
Frequently Asked Questions
What is clinical trial NCT06305247 about?
NCT06305247 is a clinical study titled "A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours". The purpose of this study is to determine the appropriate dosage, safety and effectiveness of the study drug, IPN01194 in adults with advanced solid tumours. The participants in this study will have advanced solid tumours. 'Advanced solid tumours' refers to cancers that can occur in several places,...
What is the current status of trial NCT06305247?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 220 participants. The study started on 2024-04-03. Estimated completion is 2028-03-20.
What conditions does trial NCT06305247 study?
This clinical trial studies the following conditions: Colorectal Cancer, Melanoma, Solid Tumor, Head and Neck Squamous Cell Carcinoma, Pancreatic Ductal Adenocarcinoma.
What interventions are being tested in trial NCT06305247?
The interventions under investigation include: IPN01194 (DRUG).
Who is sponsoring clinical trial NCT06305247?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06305247 being conducted?
This trial has 12 study locations across California, Connecticut, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06305247's enrollment target sits among peer trials
220 139th of 381 higher than 241 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI